Monomethyl auristatin E
Safety Information
Hazard Statements
Precautionary Statements
Pictograms
Product Description
Monomethyl auristatin E (MMAE) is a potent anticancer agent developed through chemical synthesis. It belongs to the class of drugs known as auristatins, which are cytotoxic agents designed to target cancer cells. MMAE works by inhibiting tubulin polymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cells. This compound has shown promise in preclinical studies for its ability to effectively treat various types of cancers, including breast, lung, and ovarian cancers. Its mechanism of action sets it apart from traditional chemotherapy drugs, offering a new approach to cancer treatment.
Application
MMAE is primarily used in research settings to study its antitumor effects and potential therapeutic applications. It serves as a valuable tool in drug discovery efforts aimed at developing more effective treatments for cancer. Additionally, MMAE can be utilized in the development of antibody-drug conjugates (ADCs), a type of targeted therapy that combines the specificity of monoclonal antibodies with the potency of MMAE to deliver the drug directly to cancer cells.
Articles:
- Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates
Publication Date: 24 December 2018
Filip S. Ekholm, Suvi-Katriina Ruokonen, Marina Redón, Virve Pitkänen, Anja Vilkman, Juhani Saarinen, Jari Helin, Tero Satomaa and Susanne K. Wiedmer
https://doi.org/10.3390/separations6010001
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
Publication Date: AUGUST 15, 2003
Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer, Bruce J. Mixan, Kerry Klussman, Dana F. Chace, Starr X. Rejniak, Kristine A. Gordon, Ron DeBlanc, Brian E. Toki, Che-Leung Law, Svetlana O. Doronina, Clay B. Siegall, Peter D. Senter, Alan F. Wahl
https://doi.org/10.1182/blood-2003-01-0039
- CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Publication Date: FEBRUARY 17 2006
Kam Fai Tse; Michael Jeffers; Vincent A Pollack; Denise A McCabe; Melanie L Shadish; Nikolai V Khramtsov; Craig S Hackett; Suresh G Shenoy; Bing Kuang; Ferenc L Boldog; John R MacDougall; Luca Rastelli; John Herrmann; Michael Gallo; Gadi Gazit-Bornstein; Peter D Senter; Damon L Meyer; Henri S Lichenstein; William J LaRochelle